Press release, Helsinki, 6 May 2024 at 9 AM (EEST) Health Canada Approves Nexstim NBS 6 System for Treatment of MDD Nexstim Plc (NXTMH:HEX) ('Nexstim' or 'Company') has received approval from Health Canada for the marketing and commercial distribution of its NBS 6 system for the treatment of Major Depressive Disorder (MDD).

新闻稿，赫尔辛基，2024年5月6日上午9点（EEST），加拿大卫生部批准用于治疗MDD的Nexstim NBS 6系统Nexstim Plc（NXTMH:HEX）（“Nexstim”或“公司”）已获得加拿大卫生部的批准，用于销售和商业分销其用于治疗重度抑郁症（MDD）的NBS 6系统。

Released in the EU and the United States in 2023, the NBS 6 is a new generation Nexstim system. The NBS 6 is currently FDA-approved for the treatment of major depressive disorder (MDD), and CE marked for the treatment of major depression and chronic neuropathic pain. One of the unique features of the NBS 6 is its modular design that allows for expansions of system capabilities over time.

NBS 6于2023年在欧盟和美国发布，是新一代Nexstim系统。NBS 6目前被FDA批准用于治疗重度抑郁症（MDD），CE标记用于治疗重度抑郁症和慢性神经性疼痛。NBS 6的一个独特功能是其模块化设计，可以随着时间的推移扩展系统功能。

Mikko Karvinen, CEO of Nexstim, comments: “We have been happy with the progress made with the release of the NBS 6, and this Health Canada approval gets us one step further on our commercial expansion journey. We continue to be actively present in the Canadian market, working closely together with our local distributor Canadian Health Solutions (CHS).” Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO +358 50 326 4101 mikko.karvinen@nexstim.com About Nexstim Plc Nexstim is a Finnish, globally operating growth-oriented medical technology company.

Nexstim首席执行官Mikko Karvinen评论道：“我们对NBS 6的发布所取得的进展感到高兴，加拿大卫生部的这一批准使我们在商业扩张的道路上迈出了一步。我们继续积极参与加拿大市场，与我们当地的分销商加拿大卫生解决方案（CHS）密切合作。”更多信息请访问网站www.Nexstim.com，或联系：Mikko Karvinen，CEO+358 50 326 4101mikko.karvinen@nexstim.com关于Nexstim Plc Nexstim是一家芬兰的全球运营增长型医疗技术公司。

Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

我们的使命是为挑战性的脑部疾病和紊乱提供个性化和有效的诊断和治疗。Nexstim开发了一种世界领先的非侵入性脑刺激技术，用于导航经颅磁刺激（nTMS），具有高度复杂的3D导航，可将TMS准确且个性化地定位到大脑的特定区域。

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain St.

Nexstim的诊断业务专注于导航大脑St的商业化。

Attachment

附件

Nexstim Plc_Press release_Canada approval_06052024_FINAL

Nexstim Plc\u新闻稿\u加拿大批准\u 06052024\u最终